Initiation of TNF inhibitor therapy and change in physiologic measures in psoriasis

Journal of the European Academy of Dermatology and Venereology

Volumn 28, Issue 10, 2014, Pages 1380-1387

  Wu, J J ^a   Liu, L ^b   Asgari, M M ^b,c   Curtis, J R ^d   Harrold, L ^e   Salman, C ^b   Herrinton, L J ^b  

^a KAISER PERMANENTE MEDICAL CENTER   (United States)

^b DIVISION OF RESEARCH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d University of Alabama at Birmingham   (United States)

^e UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; LIPID; METHOTREXATE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR INHIBITOR; DERMATOLOGICAL AGENT; GLUCOSE BLOOD LEVEL; INFLIXIMAB; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CLINICAL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OBESITY; PHOTOTHERAPY; PSORIASIS; RETROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT INDICATION; TRIACYLGLYCEROL BLOOD LEVEL; ANTAGONISTS AND INHIBITORS; BLOOD; BLOOD PRESSURE; ENERGY METABOLISM; FEMALE; FOLLOW UP; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; DERMATOLOGIC AGENTS; ENERGY METABOLISM; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIPIDS; MALE; METHOTREXATE; MIDDLE AGED; PHOTOTHERAPY; PSORIASIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84908099130     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12296     Document Type: Article

References (31)

1. Ahlehoff O, Gislason GH, Charlot M, et al,. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med 2011; 270: 147-157.
2. Ahlehoff O, Gislason GH, Jørgensen CH, et al,. Psoriasis and risk of atrial fibrillation and ischaemic stroke: a Danish Nationwide Cohort Study. Eur Heart J 2012; 33: 2054-2064.
3. Ahlehoff O, Gislason GH, Lindhardsen J, et al,. Psoriasis carries an increased risk of venous thromboembolism: a Danish nationwide cohort study. PLoS ONE 2011; 6: e18125.
4. Wakkee M, Meijer W, Neumann HA, Herings RM, Nijsten T,. Psoriasis may not be an independent predictor for the use of cardiovascular and anti-diabetic drugs: a 5-year prevalence study. Acta Derm Venereol 2009; 89: 476-483.
5. Wakkee M, Herings RM, Nijsten T,. Psoriasis may not be an independent risk factor for acute ischemic heart disease hospitalizations: results of a large population-based Dutch cohort. J Invest Dermatol 2010; 130: 962-967.
6. Qureshi AA, Choi HK, Setty AR, Curhan GC,. Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. Arch Dermatol 2009; 145: 379-382.
7. Love TJ, Qureshi AA, Karlson EW, Gelfand JM, Choi HK,. Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003-2006. Arch Dermatol 2011; 147: 419-424.
8. Koebnick C, Black MH, Smith N, et al,. The association of psoriasis and elevated blood lipids in overweight and obese children. J Pediatr 2011; 159: 577-583.
9. Gelfand JM, Dommasch ED, Shin DB, et al,. The risk of stroke in patients with psoriasis. J Invest Dermatol 2009; 129: 2411-2418.
10. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB,. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735-1741.
11. Mehta NN, Yu Y, Pinnelas R, et al,. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med 2011; 124: 775.e1-775.e6
12. Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM,. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J 2010; 31: 1000-1006.
13. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM,. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55: 829-835.
14. Abuarbara K, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM,. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol 2010; 163: 586-592.
15. Langan SM, Seminara NM, Shin DB, et al,. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol 2012; 132 (3 Pt 1): 556-562.
16. Cohen AD, Sherf M, Vidavsky L, Vardy DA, Shapiro J, Meyerovitch J,. Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology 2008; 216: 152-155.
17. Cohen AD, Gilutz H, Henkin Y, et al,. Psoriasis and the metabolic syndrome. Acta Derm Venereol 2007; 87: 506-509.
18. Gelfand JM, Yeung H,. Metabolic syndrome in patients with psoriatic disease. J Rheumatol Suppl 2012; 89: 24-28.
19. Bongartz T, Kudva Y,. Can treatment of chronic inflammatory diseases reduce the risk of diabetes mellitus? JAMA 2011; 305: 2573-2574.
20. Ryan C, Leonardi CL, Krueger JG, et al,. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA 2011; 306: 864-871.
21. Ahlehoff O, Skov L, Gislason G, et al,. Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study. J Intern Med 2013; 273: 197-204.
22. Wu JJ, Poon KT, Channual JC, Shen AY,. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol 2012; 148: 1244-1250.
23. Abuabara K, Lee H, Kimball AB,. The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study. Br J Dermatol 2011; 165: 1066-1073.
24. Solomon DH, Massarotti E, Garg R, Liu J, Canning C, Schneeweiss S,. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA 2011; 305: 2525-2531.
25. Stern RS,. Psoriasis is not a useful independent risk factor for cardiovascular disease. J Invest Dermatol 2010; 130: 917-919.
26. Esposite M, Mazzotta A, Saraceno R, Schipani C, Chimenti S,. Influence and variation of the body mass index in patients treated with etanercept for plaque-type psoriasis. Int J Immunopathol Pharmacol 2009; 22: 219-225.
27. Gisondi P, Cotena C, Tessari G, Girolomoni G,. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol 2008; 22: 341-344.
28. Saraceno R, Schipani C, Mazzotta A, et al,. Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis. Pharmacol Res 2008; 57: 290-295.
29. Renzo LD, Saraceno R, Schipani C, et al,. Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-α treatment. Dermatol Ther 2011; 24: 446-451.
30. Gordon NP,. How Does the Adult Kaiser Permanente Membership in Northern California Compare with the Larger Community? Kaiser Permanente Division of Research, Oakland, CA, 2006. Available from: http://www.dor.kaiser.org/dor/mhsnet/public/kpnc-community.htm.
31. Asgari MM, Wu JJ, Gelfand JM, et al,. Validity of diagnostic codes and prevalence of psoriasis and psoriatic arthritis in a managed care population, 1996-2009. Pharmacoepidemiol Drug Saf 2013; 22: 842-849.